Zobrazeno 1 - 10
of 580
pro vyhledávání: '"C Zahn"'
Autor:
Kanika Vanshylla, Jeroen Tolboom, Kathryn E. Stephenson, Karin Feddes-de Boer, Annemiek Verwilligen, Sietske Karla Rosendahl Huber, Lucy Rutten, Hanneke Schuitemaker, Roland C. Zahn, Dan H. Barouch, Frank Wegmann
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-7 (2024)
Abstract The failure of human vaccine efficacy trials assessing a mosaic HIV-1 vaccine calls into question the translatability of preclinical SHIV challenge studies that demonstrated high efficacy of this vaccine in primates. Here we present a post h
Externí odkaz:
https://doaj.org/article/24815bba35614e328f16b8f216a011f6
Autor:
Annemart Koornneef, Kanika Vanshylla, Gijs Hardenberg, Lucy Rutten, Nika M. Strokappe, Jeroen Tolboom, Jessica Vreugdenhil, Karin Feddes-de Boer, Aditya Perkasa, Sven Blokland, Judith A. Burger, Wei-Chiao Huang, Jonathan F. Lovell, Danielle van Manen, Rogier W. Sanders, Roland C. Zahn, Hanneke Schuitemaker, Johannes P. M. Langedijk, Frank Wegmann
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipi
Externí odkaz:
https://doaj.org/article/b47f9ae471c641c184638edf81cb1133
Autor:
Sonia Marquez-Martinez, Selina Khan, Joan van der Lubbe, Laura Solforosi, Lea M. M. Costes, Ying Choi, Satish Boedhoe, Mieke Verslegers, Marjolein van Heerden, Wendy Roosen, Sandra De Jonghe, Hendy Kristyanto, Veronica Rezelj, Jenny Hendriks, Jan Serroyen, Jeroen Tolboom, Frank Wegmann, Roland C. Zahn
Publikováno v:
Vaccines, Vol 12, Iss 5, p 559 (2024)
Ad26.COV2.S vaccination can lead to vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe adverse effect, characterized by thrombocytopenia and thrombosis. The mechanism of VITT induction is unclear and likely multifactorial, p
Externí odkaz:
https://doaj.org/article/0b70c99c6c794addab88f4e0e602e414
Autor:
Laura Solforosi, Lea M. M. Costes, Jeroen T. B. M. Tolboom, Katherine McMahan, Tochi Anioke, David Hope, Tetyana Murdza, Michaela Sciacca, Emily Bouffard, Julia Barrett, Cindy Wu, Nicole Hachmann, Jessica Miller, Jingyou Yu, Xuan He, Catherine Jacob-Dolan, Sietske K. Rosendahl Huber, Liesbeth Dekking, Ronnie Chamanza, Ying Choi, Karin Feddes-de Boer, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Variant booster vaccines are a strategy to improve protection against SARS-CoV-2. Here, the authors find that both Wuhan-Hu-1-based Ad26.COV2.S or an Omicron-adapted booster vaccine provide robust immune responses and protection against Omicron in NH
Externí odkaz:
https://doaj.org/article/48f5d6d725c04fbe926ebad22c4e7481
Autor:
Eirikur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Freek Cox, Jan Serroyen, Matthew J. Jorgensen, Johannes P. M. Langedijk, Hanneke Schuitemaker, Benoit Callendret, Roland C. Zahn
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral v
Externí odkaz:
https://doaj.org/article/28de2b060bbe418f87ca844fbb52ad64
Autor:
Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-13 (2022)
Abstract The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to
Externí odkaz:
https://doaj.org/article/d491b13699db469ebcfbd2dc8b441508
Autor:
Selina Khan, Sonia Marquez-Martinez, Tim Erkens, Adriaan de Wilde, Lea M. M. Costes, Petra Vinken, Sandra De Jonghe, Wendy Roosen, Chiara Talia, Ronnie Chamanza, Jan Serroyen, Jeroen Tolboom, Roland C. Zahn, Frank Wegmann
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1792 (2023)
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a very rare but serious adverse reaction that can occur after Ad26.COV2.S vaccination in humans, leading to thrombosis at unusual anatomic sites. One hypothesis is that accidental intraveno
Externí odkaz:
https://doaj.org/article/bfc0bc02614c4b6aaebfac4c8308c882
Autor:
Shant H. Mahrokhian, Lisa H. Tostanoski, Catherine Jacob-Dolan, Roland C. Zahn, Frank Wegmann, Katherine McMahan, Jingyou Yu, Makda S. Gebre, Esther A. Bondzie, Huahua Wan, Olivia Powers, Tianyi Ye, Julia Barrett, Hanneke Schuitemaker, Dan H. Barouch
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Emerging SARS-CoV-2 variants with the potential to escape binding and neutralizing antibody responses pose a threat to vaccine efficacy. We recently reported expansion of broadly neutralizing activity of vaccine-elicited antibodies in humans
Externí odkaz:
https://doaj.org/article/e81f9a919d68445d8accd817d3d2a103
Autor:
Lisa H. Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Aiquan Chang, Olivia C. Powers, Daniel Sellers, Sarah Gardner, Julia Barrett, Owen Sanborn, Kathryn E. Stephenson, Jessica L. Ansel, Kate Jaegle, Michael S. Seaman, Maciel Porto, Megan Lok, Brittany Spence, Kathleen Cayer, Danielle Nase, Shaikim Holman, Heath Bradette, Swagata Kar, Hanne Andersen, Mark G. Lewis, Freek Cox, Jeroen T. B. M. Tolboom, Anne Marit de Groot, Dirk Heerwegh, Mathieu Le Gars, Jerald Sadoff, Frank Wegmann, Roland C. Zahn, Hanneke Schuitemaker, Dan H. Barouch
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-6 (2022)
Abstract SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in
Externí odkaz:
https://doaj.org/article/2a0525ec444a4d9db1584cc060807b28
Autor:
Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, Ying Choi, Miranda R. M. Baert, Karin Feddes-de Boer, Ana Izquierdo Gil, Marjolein van Heerden, Tim J. Dalebout, Sebenzile K. Myeni, Marjolein Kikkert, Eric J. Snijder, Leon de Waal, Koert J. Stittelaar, Jeroen T. B. M. Tolboom, Jan Serroyen, Leacky Muchene, Leslie van der Fits, Lucy Rutten, Johannes P. M. Langedijk, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human
Externí odkaz:
https://doaj.org/article/fc2cb2bea71d44b4a49590c0dc2b55f2